Greytown Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,869
| Closed | -$211K | – | 73 |
|
|
2024
Q1 | $211K | Sell |
4,869
-1,426
| -23% | -$58.8K | 0.12% | 70 |
|
|
2023
Q4 | $236K | Hold |
6,295
| – | – | 0.13% | 73 |
|
|
2023
Q3 | $232K | Sell |
6,295
-3,443
| -35% | -$122K | 0.13% | 71 |
|
|
2023
Q2 | $348K | Hold |
9,738
| – | – | 0.19% | 50 |
|
|
2023
Q1 | $348K | Sell |
9,738
-2,375
| -20% | -$83.1K | 0.18% | 63 |
|
|
2022
Q4 | $427K | Sell |
12,113
-47
| -0.4% | -$1.57K | 0.23% | 57 |
|
|
2022
Q3 | $360K | Sell |
12,160
-3,022
| -20% | -$115K | 0.22% | 61 |
|
|
2022
Q2 | $833K | Sell |
15,182
-3,715
| -20% | -$205K | 0.47% | 39 |
|
|
2022
Q1 | $1.04M | Sell |
18,897
-7,317
| -28% | -$397K | 0.5% | 37 |
|
|
2021
Q4 | $1.46M | Sell |
26,214
-1,996
| -7% | -$104K | 0.62% | 29 |
|
|
2021
Q3 | $1.36M | Buy |
28,210
+2,426
| +9% | +$122K | 0.61% | 33 |
|
|
2021
Q2 | $1.3M | Buy |
25,784
+7,237
| +39% | +$348K | 0.63% | 27 |
|
|
2021
Q1 | $828K | Buy |
18,547
+4,601
| +33% | +$209K | 0.41% | 47 |
|
|
2020
Q4 | $647K | Buy |
13,946
+4,872
| +54% | +$224K | 0.44% | 42 |
|
|
2020
Q3 | $430K | Buy |
9,074
+3,500
| +63% | +$175K | 0.35% | 51 |
|
|
2020
Q2 | $290K | Sell |
5,574
-6,996
| -56% | -$359K | 0.27% | 59 |
|
|
2020
Q1 | $604K | Sell |
12,570
-4,573
| -27% | -$244K | 0.6% | 39 |
|
|
2019
Q4 | $1.01M | Sell |
17,143
-164
| -0.9% | -$9.12K | 0.72% | 29 |
|
|
2019
Q3 | $929K | Buy |
17,307
+489
| +3% | +$25.2K | 0.69% | 30 |
|
|
2019
Q2 | $849K | Sell |
16,818
-7,149
| -30% | -$359K | 0.61% | 35 |
|
|
2019
Q1 | $1.26M | Hold |
23,967
| – | – | 0.91% | 21 |
|
|
2018
Q4 | $1.16M | Buy |
23,967
+429
| +2% | +$21.1K | 0.83% | 21 |
|
|
2018
Q3 | $1.19M | Sell |
23,538
-4,548
| -16% | -$231K | 0.79% | 22 |
|
|
2018
Q2 | $1.43M | Buy |
28,086
+186
| +0.7% | +$9.37K | 0.67% | 21 |
|
|
2018
Q1 | $1.38M | Buy |
27,900
+1,424
| +5% | +$66.3K | 0.69% | 21 |
|
|
2017
Q4 | $1.18M | Buy |
26,476
+7,730
| +41% | +$357K | 0.61% | 29 |
|
|
2017
Q3 | $958K | Buy |
18,746
+9,198
| +96% | +$467K | 0.55% | 34 |
|
|
2017
Q2 | $520K | Buy |
9,548
+461
| +5% | +$24.6K | 0.42% | 34 |
|
|
2017
Q1 | $485K | Sell |
9,087
-1,202
| -12% | -$61K | 0.43% | 35 |
|
|
2016
Q4 | $496K | Buy |
+10,289
| New | +$508K | 0.48% | 35 |
|
Other funds holding GSK
JEST
Greytown Advisors's GSK Position: Q2 2024 in Review
Greytown Advisors sold out of GSK (GSK) in Q2 2024, closing a stake of 4,869 shares — an estimated $211K sold.
Greytown Advisors first reported a position in GSK in Q4 2016 and held it in 30 quarters. The position peaked at $1.46M in Q4 2021. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.
- Greytown Advisors reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
- Greytown Advisors sold 4,869 GSK shares in Q2 2024, an estimated $211K.
- Greytown Advisors first reported a position in GSK in Q4 2016 and held it in 30 quarters.
- Greytown Advisors's GSK position peaked at $1.46M in Q4 2021.
- 884 funds tracked by Wall St. Rank held GSK as of Q2 2024.
Based on Greytown Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.